Summary of use during lactation
No information is available on the clinical use of lisocabtagene maraleucel during breastfeeding nor on breastfeeding after CAR-T cell therapy with lisocabtagene maraleucel. However, some information on other agents indicates that breastfeeding might be acceptable after CAR-T cell therapy. If breastfeeding is attempted following lisocabtagene maraleucel CAR T-cell therapy, infants should be monitored carefully, particularly with B- and T-cell counts and immunoglobulin (IgA, IgG and IgM) blood levels.
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
Axicabtagene Ciloleucel
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.